摘要
目的:分析头孢哌酮舒巴坦钠治疗慢性阻塞性肺疾病急性加重期的效果。方法:选取贺州市人民医院2022年1月—2023年10月收治的120例慢性阻塞性肺疾病急性加重期患者为研究对象,按照随机数字表法分为对照组和观察组,各60例。对照组采取哌拉西林钠他唑巴坦钠治疗,观察组采取头孢哌酮舒巴坦钠治疗。对比两组炎性因子水平、临床症状消失时间以及不良反应发生情况。结果:治疗后,两组降钙素原、C反应蛋白水平降低,观察组低于对照组(P<0.05);观察组咳嗽咳痰、气短气促、湿性啰音症状消失时间短于对照组(P<0.001);两组不良反应发生率对比,无统计学差异(P>0.05)。结论:头孢哌酮舒巴坦钠治疗能够降低慢性阻塞性肺疾病急性加重期患者的炎性因子水平,缓解临床症状,且具有一定的安全性。
Objective:To analyze the effect of cefoperazone and sulbactam sodium in the treatment of acute exacerbation of chronic obstructive pulmonary disease.Methods:A total of one hundred and twenty patients with acute exacerbation of chronic obstructive pulmonary disease admitted to Hezhou People's Hospital from January 2022 to October 2023 were selected as the study objects,and were divided into control group and observation group according to random number table method,with sixty cases in each group.The control group was treated with piperacillin sodium and tazobactam sodium,and the observation group was treated with cefoperazone and sulbactam sodium.The levels of inflammatory factors,the time for clinical symptoms to disappear and the occurrence of adverse reactions were compared between the two groups.Results:After treatment,the levels of procalcitonin and C-reactive protein in the observation group were lower than those in the control group(P<0.05);the disappearance time of cough and sputum,shortness of breath and moist rales in observation group was shorter than that in control group(P<0.001);there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The treatment of cefoperazone and sulbactam sodium can reduce the level of inflammatory factors in patients with acute exacerbation of chronic obstructive pulmonary disease,relieve clinical symptoms,and has a certain safety.
作者
陈秀娟
Chen Xiujuan(Hezhou People's Hospital,Hezhou 542899,Guangxi Zhuang Autonomous Region,China)
出处
《中外医药研究》
2024年第31期90-92,共3页
JOURNAL OF CHINESE AND FOREIGN MEDICINE AND PHARMACY RESEARCH
关键词
头孢哌酮舒巴坦钠
慢性阻塞性肺疾病急性加重期
哌拉西林钠他唑巴坦钠
炎性因子
Cefoperazone and sulbactam sodium
Acute exacerbation of chronic obstructive pulmonary disease
Piperacillin sodium and tazobactam sodium
Inflammatory factor
